Statins are usually used in AMI patients due to its strong anti-lipidemic effect, pleiotropic effect and tolerable safety profiles. Generally AMI patients are prescribed many drugs concomitantly; there are some risks due to the drug interaction. Especially, statins are reported to have many drug interactions, these might influence to therapeutic prognosis and safety in AMI patients. This study is conducted to administer the non-CYP3A4 metabolized statin, pitavastatin to AMI patients over 1 year, and the results will be compared with the other results from the KAMIR study which is expected to the large scale of AMI patients using statins be enrolled. Finally, from that comparison, we will investigate the influence of the statins metabolism by CYP3A4 to the therapeutic prognosis like death, major adverse cardiac events(MACE), and major ADR of statins like CK increase, myalgia.
Study Type
OBSERVATIONAL
Enrollment
1,128
Cardiac and Vascular Center, Hanseo Hospital
Busan, South Korea
Departments of Cardiology, Catholic University of Daegu College of Medicine
Daegu, South Korea
Division of Cardiology, Department of Internal Medicine, School of Medicine, Keimyung University
Daegu, South Korea
Division of Cardiology, Heart Center, Konyang University
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Department of Cardiovascular Medicine, Wonkwang University School of Medicine
Iksan, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Division of Cardiology Cardiac Center, Seoul National University Bundang Hospital
Seongnam, South Korea
Cardiovascular Center, Korea University Guro Hospital
Seoul, South Korea
Heart Center, Division of Cardiology, Chung-Ang University Hospital
Seoul, South Korea
Death/MACE for 1 year after the registration
Time frame: 1 year
Achievement of LDL cholesterol target level according to the NCEP ATP III guideline
Time frame: 1 year
Abnormal change of lab value including CK etc
Time frame: 1 year
Adverse event including myalgia
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.